VivoSeq
Other

Cycling

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Cycling is an early-stage landscape with 0 programs across 1 company. The most active players are Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed4 · 57%
Not yet recruiting2 · 29%
Withdrawn1 · 14%

Clinical Trials

Trial Activity

7 trials

An Exploratory Clinical Study on the Protective Effect of Cycling on the Ankle Joint in Gout
Not yet recruiting·—·N/A·NCT07312396·90 enrolled
Prevention of Relapse Through Cognitive Cycling in Patients With Alcohol Use Disorder Following Alcohol Withdrawal: Protocol for the TUA-VelCo Randomised Controlled Trial
Not yet recruiting·Centre Hospitalier Esquirol·Preclinical·NCT07690423·128 enrolled
Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS
Completed·YYale University·Phase 1·NCT02124941·6 enrolled
Zolpidem's Effects on Road Cycling Performance
Completed·—·Phase 4·NCT06800378·15 enrolled
Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women
Completed·Pfizer logoPfizer·Phase 1·NCT00319163·26 enrolled
Eccentric Cycling Exercise During Pulmonary Rehabilitation in Pulmonary Vascular Disease
Completed·UUniversity of Zurich·Preclinical·NCT06480656·40 enrolled
Study Evaluating the Bioequivalence of Levonorgestrel/Ethinyl Estradiol Combinations in Cycling Women
Withdrawn·Pfizer logoPfizer·Phase 1·NCT00447863

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)